Predictors of progression in systemic sclerosis patients with interstitial lung disease
Top Cited Papers
Open Access
- 20 February 2020
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (5) , 1902026
Abstract
Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5–9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.Keywords
Funding Information
- Boehringer Ingelheim (N/A)
This publication has 100 references indexed in Scilit:
- Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung diseaseRheumatology, 2012
- Subclinical Interstitial Lung Disease: Why You Should CareAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo GroupArthritis & Rheumatism, 2011
- Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohortArthritis Research & Therapy, 2010
- High-resolution computed tomography and scleroderma lung diseaseRheumatology, 2008
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals of the Rheumatic Diseases, 2007
- Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis–associated interstitial lung disease are not predictive of disease progressionArthritis & Rheumatism, 2007
- Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function declineArthritis Care & Research, 2006
- The natural course of progressive systemic sclerosis patients with interstitial lung involvementClinical Rheumatology, 2006